DrugPatentWatch Database Preview
Fluvoxamine maleate - Generic Drug Details
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What are the generic drug sources for fluvoxamine maleate and what is the scope of freedom to operate?
Fluvoxamine maleate
is the generic ingredient in three branded drugs marketed by Actavis Elizabeth, Anchen Pharms, Torrent, Jazz Pharms, Ani Pharms Inc, Apotex, Eci Pharms Llc, Heritage Pharma, Mylan, Sun Pharm Industries, Synthon Pharms, Teva, Upsher Smith Labs, Ani Pharms, and Solvay, and is included in nineteen NDAs. There is one patent protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.Fluvoxamine maleate has twenty-four patent family members in eighteen countries.
There are eleven drug master file entries for fluvoxamine maleate. Ten suppliers are listed for this compound.
Summary for fluvoxamine maleate
| International Patents: | 24 |
| US Patents: | 1 |
| Tradenames: | 3 |
| Applicants: | 15 |
| NDAs: | 19 |
| Drug Master File Entries: | 11 |
| Suppliers / Packagers: | 10 |
| Bulk Api Vendors: | 113 |
| Clinical Trials: | 5 |
| Patent Applications: | 1,373 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price trends for fluvoxamine maleate |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for fluvoxamine maleate |
| DailyMed Link: | fluvoxamine maleate at DailyMed |
Recent Clinical Trials for fluvoxamine maleate
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Haining Health-Coming Biotech Co., Ltd. | Phase 2 |
| Guangdong General Hospital | Phase 4 |
| Meiji Seika Pharma Co., Ltd. | Phase 3 |
Recent Litigation for fluvoxamine maleate
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Elan Pharma International Limited v. Anchen Pharmaceuticals Inc |
Pharmacology for fluvoxamine maleate
| Drug Class | Serotonin Reuptake Inhibitor |
| Mechanism of Action | Serotonin Uptake Inhibitors |
Medical Subject Heading (MeSH) Categories for fluvoxamine maleate
Synonyms for fluvoxamine maleate
| (2-aminoethoxy)({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene})amine; but-2-enedioic acid |
| (E)-5-Methoxy-1-(4-(trifluoromethyl)phenyl)-1-pentanone O-(2-aminoethyl)oxime (Z)-2-butenedioate (1:1) |
| (E)-5-Methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-one O-(2-aminoethyl) oxime maleate |
| (E)-5-Methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-one O-(2-aminoethyl)oxime maleate |
| (E)-5-methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-one O-2-aminoethyl oxime maleate |
| (E)-5-Methoxy-1-[4-(trifluoromethyl)phenyl)-1-pent |
| (E)-5-Methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone O-(2-Aminoethyl)oxime Maleate |
| (E)-5-Methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone-O-(2-aminoethyl)oxime maleate |
| (E)-5-Methoxy-1-[4-(triflurormethyl)phenyl]-1-pentanone O-(2-Aminoethyl)oxime Maleate |
| (E)-Fluvoxamine Maleate |
| (Z)-2-butenedioic acid; 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine |
| (Z)-but-2-enedioic acid; 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine |
| (Z)-but-2-enedioic acid; 2-[(Z)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine |
| (Z)-but-2-enedioic acid;2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine |
| 1-Pentanone, 5-methoxy-1-(4-(trifluoromethyl)phenyl)-, O-(2-aminoethyl)oxime, (E)-, (Z)-2-butenedioate (1:1) |
| 1-Pentanone, 5-methoxy-1-(4-(trifluoromethyl)phenyl)-, O-(2-aminoethyl)oxime,(E)-, (Z)-2-butenedioate (1:1) |
| 1246666-24-9 |
| 2-[({(1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene}amino)oxy]ethanamine (2Z)-but-2-enedioate |
| 5-Methoxy-4'-(trifluoromethyl)valerophenone (E)-O-(2-aminoethyl)oxime, maleate (1:1) |
| 5-Methoxy-4'-trifluoromethylvalerophenone (E)-O-2-aminoethyloxime monomaleate |
| 54739-18-3 |
| 54739-18-3 (Parent) |
| 54739-20-7 |
| 5LGN83G74V |
| 61718-82-9 |
| 739F183 |
| A833394 |
| AB2000054 |
| AC-9541 |
| AC1NTMLT |
| AKOS015855869 |
| AKOS015906773 |
| AKOS015961142 |
| AKOS030242722 |
| AN-39241 |
| ANW-64083 |
| API0002751 |
| AS-11790 |
| AX8016087 |
| BCP06470 |
| BG0368 |
| C15H21F3N2O2.C4H4O4 |
| C19H25F3N2O6 |
| CCG-213494 |
| CHEBI:5139 |
| CHEMBL1409 |
| CPD000466268 |
| CS-1839 |
| CTK8C0093 |
| D00824 |
| Depromel |
| DTXSID3042558 |
| DU-23000 |
| DU23000 |
| Dumirox |
| EN300-122372 |
| EU-0100495 |
| F 2802 |
| F0858 |
| Faverin |
| Fevarin |
| Floxyfral |
| fluvoxamin e |
| Fluvoxamine (maleate) |
| Fluvoxamine for system suitability, European Pharmacopoeia (EP) Reference Standard |
| Fluvoxamine maleate (JP17/USAN) |
| Fluvoxamine maleate [USAN:USP] |
| Fluvoxamine maleate [USAN] |
| Fluvoxamine maleate, 1.0 mg/mL in methanol ((as free base)), certified reference material |
| Fluvoxamine maleate, British Pharmacopoeia (BP) Reference Standard |
| Fluvoxamine maleate, European Pharmacopoeia (EP) Reference Standard |
| Fluvoxamine Maleate, Pharmaceutical Secondary Standard; Certified Reference Material |
| Fluvoxamine maleate, solid |
| Fluvoxamine maleate, United States Pharmacopeia (USP) Reference Standard |
| Fluvoxaminemaleate |
| FT-0626496 |
| GP8417 |
| HMS1571G11 |
| HMS2098G11 |
| HMS3261D11 |
| HMS3267A08 |
| HMS3370O21 |
| HMS3371G18 |
| HMS3373J05 |
| HMS3393E15 |
| HMS3604H15 |
| HMS3654B17 |
| HMS3715G11 |
| HY-B0103A |
| J90043 |
| KB-209260 |
| KS-00000XLE |
| KS-1063 |
| LFMYNZPAVPMEGP-PIDGMYBPSA-N |
| LP00495 |
| LS-102000 |
| Luvox |
| Luvox (TN) |
| Luvox CR |
| maleic acid; 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine |
| Maveral |
| MCULE-4841680762 |
| MFCD00269809 |
| MK-264 |
| MLS000028469 |
| MLS000758271 |
| MLS001076285 |
| MLS001304717 |
| MLS001401391 |
| MLS006011983 |
| MolPort-002-885-827 |
| MolPort-003-666-870 |
| MolPort-027-714-052 |
| NCGC00093897-01 |
| NCGC00093897-02 |
| NCGC00261180-01 |
| NE47064 |
| NSC 309469 |
| NSC-309469 |
| NSC-759602 |
| NSC309469 |
| NSC759602 |
| Pharmakon1600-01505604 |
| s1336 |
| SAM001246977 |
| SCHEMBL35225 |
| SCHEMBL782847 |
| SME 3110 |
| SME-3110 |
| SMR000058449 |
| SMR000466268 |
| SMR000653482 |
| SMR004703541 |
| SR-01000075613 |
| SR-01000075613-1 |
| SR-01000075613-3 |
| SR-01000075613-4 |
| SR-01000075613-6 |
| ST24035070 |
| SW197282-4 |
| TC-063925 |
| TL8003932 |
| Tox21_500495 |
| UNII-5LGN83G74V |
| Z1583164922 |
Paragraph IV (Patent) Challenges for FLUVOXAMINE MALEATE
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| LUVOX CR | CAPSULE, EXTENDED RELEASE;ORAL | fluvoxamine maleate | 022033 | 2009-04-20 |
| LUVOX CR | CAPSULE, EXTENDED RELEASE;ORAL | fluvoxamine maleate | 022033 | 2009-04-13 |
US Patents and Regulatory Information for fluvoxamine maleate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ani Pharms | LUVOX | fluvoxamine maleate | TABLET;ORAL | 021519-002 | Dec 20, 2007 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| Sun Pharm Industries | FLUVOXAMINE MALEATE | fluvoxamine maleate | TABLET;ORAL | 076125-001 | Apr 29, 2002 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Synthon Pharms | FLUVOXAMINE MALEATE | fluvoxamine maleate | TABLET;ORAL | 075899-002 | Jan 17, 2001 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Teva | FLUVOXAMINE MALEATE | fluvoxamine maleate | TABLET;ORAL | 075893-003 | Sep 10, 2002 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for fluvoxamine maleate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Solvay | LUVOX | fluvoxamine maleate | TABLET;ORAL | 020243-001 | Dec 5, 1994 | Start Trial | Start Trial |
| Solvay | LUVOX | fluvoxamine maleate | TABLET;ORAL | 020243-004 | Dec 5, 1994 | Start Trial | Start Trial |
| Solvay | LUVOX | fluvoxamine maleate | TABLET;ORAL | 020243-003 | Dec 5, 1994 | Start Trial | Start Trial |
| Solvay | LUVOX | fluvoxamine maleate | TABLET;ORAL | 020243-002 | Dec 5, 1994 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for fluvoxamine maleate
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Czech Republic | 20014618 | Start Trial |
| Germany | 60035579 | Start Trial |
| Ireland | 990406 | Start Trial |
| Canada | 2698347 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2019 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.